Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702133 | 0.96 | HSD11B1 (0.44) | HSD11B1EPHX2RORCRIPK1CYP2D6 | |
| SCHEMBL21991871 | 0.94 | HSD11B1 (0.46) | HSD11B1EPHX2RORCRIPK1CYP2D6 | |
| SCHEMBL18702006 | 0.82 | HSD11B1 (0.59) | HSD11B1EPHX2CYP2D6CYP2C9CYP1A2 | |
| SCHEMBL18701822 | 0.82 | HSD11B1 (0.48) | HSD11B1EPHX2RIPK1CYP2D6CYP2C9 | |
| SCHEMBL20469388 | 0.82 | VNN1 (0.40) | EPHX2USP2 | |
| SCHEMBL31575292 | 0.77 | LMNA (0.40) | HSD11B1EPHX2RIPK1CYP1A2GRM5 | |
| SCHEMBL18702012 | 0.77 | EPHX2 (0.33) | HSD11B1EPHX2RIPK1 | |
| SCHEMBL18701846 | 0.77 | HSD11B1 (0.50) | HSD11B1EPHX2RIPK1CYP2D6CYP2C9 | |
| SCHEMBL12208870 | 0.77 | EPHX2 (0.33) | HSD11B1EPHX2RIPK1SPR | |
| SCHEMBL18701825 | 0.77 | HSD11B1 (0.46) | HSD11B1EPHX2RIPK1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-10329278-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | HSD11B1 23/4885EPHX2 2906/4885RORC 3328/4885 |
| US-10329278-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | HSD11B1 1419/4885EPHX2 1493/4885RORC 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.